Tuning antibody stability and function by rational designs of framework mutations
Artificial intelligence and machine learning models have been developed to engineer antibodies for specific recognition of antigens. These approaches, however, often focus on the antibody complementarity-determining region (CDR) whilst ignoring the immunoglobulin framework (FW), which provides structural rigidity and support for the flexible CDR loops. Here we present an integrated computational-experimental workflow, combining static structure analyses, molecular dynamics simulations and <i>in vitro</i> physicochemical and functional assays to generate rational designs of FW mutations for modulating antibody stability and activity. We first showed that recent antibody-specific language models lacked insights in FW mutagenesis, in comparison to approaches that use antibody structure information. Using the widely used breast cancer therapeutic trastuzumab as a use case, we designed stabilizing mutants which were distal to the CDR and preserved the antibody's functionality to engage its cognate antigen (HER2) and induce antibody-dependent cellular cytotoxicity. Interestingly, guided by local backbone motions predicted using molecular dynamics simulations, we designed a FW mutation on the trastuzumab light chain that retained antigen-binding effects, but lost Fab-mediated and Fc-mediated effector functions. This highlighted the effects of FW on immunological functions engendered in distal areas of the antibody, and the importance of considering attributes other than binding affinity when assessing antibody function. Our approach incorporates interdomain dynamics and distal effects between FW and the Fc domains, expands the scope of antibody engineering beyond the CDR, and underscores the importance of a holistic perspective that considers the entire antibody structure in optimizing antibody stability, developability and function.
Authors
- Dongjun Guo (ORCID: https://orcid.org/0009-0004-1037-9269)
- Joseph Ng (ORCID: https://orcid.org/0000-0002-3617-5211)
- Maria Laura De Sciscio (ORCID: https://orcid.org/0000-0001-5523-0987)
- Alicia M. Chenoweth (ORCID: https://orcid.org/0000-0002-2736-9268)
- Daniela Iancu (ORCID: https://orcid.org/0000-0002-7990-6942)
- Jitesh Chauhan (ORCID: https://orcid.org/0000-0002-3968-9234)
- Franca Fraternali (ORCID: https://orcid.org/0000-0002-3143-6574)
- Alexandra McCraw (ORCID: https://orcid.org/0009-0008-2412-4389)
- Sophia N. Karagiannis (ORCID: https://orcid.org/0000-0002-4100-7810)
- Anthony Cheung (ORCID: https://orcid.org/0000-0002-2988-2786)
- Yi Liu (ORCID: https://orcid.org/0000-0002-2943-2144)
- T. Ming Chu (ORCID: https://orcid.org/0009-0003-3344-0336)
- Melanie Grandits (ORCID: https://orcid.org/0000-0001-8143-8298)
- S. Patel
- Alice Kosmider
Institutions
- Guy's Hospital (GB)
- King's College London (GB)
- European University of Rome (IT)
- University College London (GB)
- Birkbeck, University of London (GB)
Publication Details
- Journal
- mAbs
- Published
- 2025-07-13
- DOI
- https://doi.org/10.1080/19420862.2025.2532117
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Breast Cancer Now
- Worldwide Cancer Research
- British Society for Immunology
- Cancer Research UK
- King's College London
- King's Health Partners
- China Scholarship Council
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council